Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 5/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23529148 | 0.88 | USP30 (0.55) | USP30HRH3MALT1SUV39H2STS | |
| SCHEMBL1639007 | 0.80 | SUV39H2 (0.60) | SUV39H2ALK | |
| SCHEMBL31342592 | 0.80 | SUV39H2 (0.44) | SUV39H2ALKGPR119 | |
| SCHEMBL23529086 | 0.80 | ROCK2 (0.49) | USP30HRH3MALT1ALKGPR119 | |
| SCHEMBL2478632 | 0.79 | HRH3 (0.57) | USP30HRH3GPR119 | |
| SCHEMBL22396214 | 0.78 | USP30 (0.66) | USP30HRH3GPR119 | |
| SCHEMBL2633790 | 0.77 | USP30 (0.52) | USP30HRH3GPR119 | |
| SCHEMBL3078681 | 0.77 | KDM4E (0.49) | SUV39H2STS | |
| SCHEMBL17760752 | 0.77 | USP30 (0.56) | USP30HRH3GPR119 | |
| SCHEMBL12065331 | 0.77 | HRH3 (0.56) | USP30HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720545-B1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435830-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435830-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2007027734-A2 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1720545-A1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | ChemoCentryx Inc (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| US-20050234034-A1 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005084667-A1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234034-A1 | Bicyclic and bridged nitrogen heterocycles | CCR3, CCR1, CCR2 | USP30 3765/4885HRH3 74/4885MALT1 579/4885 |
| US-20060074121-A1 | Bicyclic and bridged nitrogen heterocycles | CCR3, CCR1, CCR2 | USP30 3765/4885HRH3 74/4885MALT1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.